A drug described as "the closest we have ever been to an HIV vaccine" that currently costs over $40K per person per year, could be made to cost less than $40 for each patient, according to newly-released research.
Early trials have found that Lenacapavir, developed by US pharmaceutical company Gilead, is nearly 100% effective in preventing HIV infection. The drug is also easier to administer than current preventative regimens that require daily pills, with Lenacapavir needing only two injections per year.